Biosensors soars on CE-mark for Axxion DES (drug-eluting stent)
This article was originally published in Clinica
Shares in Biosensors International surged after the company revealed on July 12 it had CE-marked sale in Europe its first product for the highly lucrative drug-eluting stent (DES) arena.
You may also be interested in...
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.